El 13 de septiembre de 2019 la Dra. Elena Magaz García (adjunta MI) nos habló sobre una actualización sobre la insuficiencia cardíaca. Durante la exposición no comentó pero si está en la presentación un repaso de los aspectos más importantes de las guía de la ESC sobre la diabetes.

• Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
  – Angiotensin Neprilysin inhibition in heart failure with preserved ejection fraction.
  – Association of change in N terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan. Treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.
  – Cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial.
  – Rivaroxaban in patients with heart failure, sinus rhythm and coronary disease.
  – Cardiorenal sindrome: classification, pathophysiology, diagnosis and treatment strategies. A scientific statement from the American Heart Association.
  Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF.
  – Ultrafiltration to decompensated heart failure with cardiorenal syndrome.
  – Efficacy and safety of spironolactone in acute heart failure. The ATHENA-HF randomized clinical.
  – Rationale and design of the ADVOR (acetazolamide in decompensated heart failure with volume overload trial.
  – Hypertonic saline with furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis.
  – Tolvaptan reduces the risk of worsening renal function in patients with acute descompensate heart failure in high risk population.
  – Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials.
  Visualizar la presentación aquí

• 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
  Se puede ver la presentación en el siguiente enlace